All In MedTech

Device Trial Radar · NCT03865667

Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Preserve Femoral Stem

Last checked: Nov 20, 2026Latest source record: Apr 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

63

Actual

Start

Jan 15, 2019

Primary completion

Jan 1, 2032

Study completion Jan 1, 2032

Sponsor

Lead sponsor
MicroPort Orthopedics Inc.Not on our public-company list
Sponsor type
Industry
First posted
Mar 7, 2019

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) components marketed in the European Union (EU). These types of studies are required by regulatory authorities for all THA devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in Europe. This study has been designed in accordance with the medial device directives (MEDDEV) 2.12/2 rev 2.

Conditions

  • Joint Disease

Interventions

  • PROFEMUR® Preserve Femoral StemDevice

    Total Hip Total Hip Arthroscopy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint is to evaluate component survivorship of the PROFEMUR® Preserve Femoral Stem and CoCr Modular Neck out to 10 years follow-up.Time frame: 10 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dr. Manel Ribas

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.